TuHURA Biosciences, Inc. (HURA) CEO granted 610,332 options in Form 4 filing

Rhea-AI Filing Summary

TuHURA Biosciences, Inc. reported an insider equity award for its Chief Executive Officer and director, James A. Bianco. On January 6, 2026, he received an award of 610,332 stock options (options right to buy common stock) with an exercise price of $0.73 per share and an expiration date of January 6, 2036. The options were granted at no cost as a supplemental option grant to one previously made in December 2025.

According to the disclosure, one-third of these stock options become exercisable on the first, second, and third anniversary of January 6, 2025, creating a three-year vesting schedule. Following this grant, Bianco beneficially owns 610,332 derivative securities directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bianco James A.

(Last) (First) (Middle)

10500 UNIVERSITY CENTER DRIVE

SUITE 110

(Street)

TAMPA FL 33612

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TuHURA Biosciences, Inc./NV [ HURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options (Right to Buy)	$0.73	01/06/2026		A		610,332		(1)	01/06/2036	Common Stock	610,332	$0	610,332	D

Explanation of Responses:

1. Represents a supplemental option grant to the option grant previously made in December 2025. One-third of the stock options become exercisable on the first, second, and third anniversary of January 6, 2025.

	/s/ Dan Dearborn as Power of Attorney for James Bianco	01/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did TuHURA Biosciences (HURA) report?

TuHURA Biosciences reported a stock option grant to its Chief Executive Officer and director, James A. Bianco, documented on a Form 4 insider trading report.

How many stock options did TuHURA CEO James Bianco receive?

James A. Bianco received 610,332 stock options, as shown in the derivative securities table of the filing.

What is the exercise price of the new TuHURA stock options?

The options granted to James A. Bianco have an exercise price of $0.73 per share for TuHURA common stock.

When do James Bianco’s TuHURA options vest?

The filing states that one-third of the stock options become exercisable on the first, second, and third anniversary of January 6, 2025, resulting in a three-year vesting schedule.

When do the TuHURA options granted to James Bianco expire?

The options have an expiration date of January 6, 2036, giving a long-term window for potential exercise.

How many derivative securities does James Bianco own after this TuHURA grant?

After the reported transaction, James A. Bianco beneficially owns 610,332 derivative securities, all held directly, according to the Form 4.

Is this TuHURA option grant related to a prior award?

Yes. A footnote explains that this represents a supplemental option grant to an option grant previously made in December 2025.